Here are the 10-Q quarterly reports from Cytek Biosciences, Inc. (CTKB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CTKB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTKB filings page.
Cytek Biosciences, Inc. (CTKB) reported third-quarter 2026 revenue of $53.2 million, compared with $52.3 million a year earlier. Gross profit increased to $31.2 million from $27.6 million, while net loss widened to $6.1 million from $5.5 million. For the first nine months, revenue was $145.5 million versus $139.4 million, and net loss was $37.1 million versus $22.5 million.
Operating cash use was $5.8 million for the nine months, compared with $3.9 million in 2025. As of September 30, 2026, cash, cash equivalents and restricted cash totaled $67.2 million, and marketable securities were $189.1 million.
In the Beckman Coulter litigation, a jury found for Cytek on three of four asserted patent claims; on the fourth, it found no literal infringement but infringement under the doctrine of equivalents. The jury awarded $56.11 million in past damages through September 30, 2025. The judgment is not final while post-trial motions remain pending; the company said the loss is reasonably possible but not probable and recorded no liability for the verdict. Both parties filed post-trial motions on October 13, 2026.
Cytek Biosciences reported total revenue of $48,140 (in thousands) for the quarter ended June 30, 2026, up from $45,602 (in thousands) a year earlier, with growth in both product and service revenue. Higher operating expenses and weaker other income led to a net loss of $12,158 (in thousands), or $(0.09) per share, compared with a loss of $5,583 (in thousands), or $(0.04) per share.
For the first six months of 2026, revenue reached $92,275 (in thousands) while net loss widened to $31,024 (in thousands). Cash and cash equivalents were $73,846 and marketable securities $188,158 as of June 30, 2026, alongside deferred revenue of $47,264 (in thousands) and a legal settlement liability of $8,721 (in thousands).
Cytek Biosciences, Inc. reported revenue of $44.1 million for the three months ended March 31, 2026, up from $41.5 million a year earlier, driven by both product and service sales. Direct sales contributed 69% of revenue, with distributors providing the remainder.
The company recorded a net loss of $18.9 million, compared with $11.4 million in the prior-year quarter, as operating expenses, particularly general and administrative costs, increased. Gross profit was $21.3 million. Cash and cash equivalents were $65.7 million and marketable securities were $196.6 million, supporting total assets of $449.1 million against total liabilities of $121.5 million.
Cytek Biosciences (CTKB) filed its Q3 2025 10‑Q, reporting total revenue of $52.3 million (product $38.1M; service $14.2M). Gross profit was $27.6 million and loss from operations was $9.2 million, resulting in a net loss of $5.5 million, or $0.04 per share.
Year‑to‑date revenue was $139.4 million with a net loss of $22.5 million. Cash and cash equivalents were $93.3 million, and marketable securities were $168.5 million. Deferred revenue was $28.7 million current and $16.3 million noncurrent, with remaining performance obligations totaling $45.1 million. Operating cash flow for the nine months was $(3.9) million. Shares outstanding were 127,864,830 as of September 30, 2025.